A retrospective study from Hunan Provincial People's Hospital looked at patients with intermediate and advanced-stage hepatocellular carcinoma. Researchers compared those receiving combination therapy with TACE plus systemic treatment against those getting TACE alone. The group involved 142 patients.
The study found that progression-free survival was similar between the two groups. However, overall survival was significantly better for patients with advanced-stage disease in the combination group. For intermediate-stage patients, survival times were comparable. Overall, there was a trend toward better survival with combination therapy, though this was not statistically significant.
Safety profiles were generally comparable between groups, with similar rates of severe adverse events. The researchers noted that tolerability was similar, especially in patients with preserved liver function.
Because this was a single-center study, the findings need confirmation. The authors highlight the importance of careful patient selection and suggest further prospective studies are needed to optimize treatment strategies for these conditions.